Illumina (NASDAQ:ILMN – Free Report) had its price objective decreased by Royal Bank of Canada from $337.00 to $328.00 in a report issued on Tuesday morning. Royal Bank of Canada currently has an outperform rating on the life sciences company’s stock.
Several other analysts also recently weighed in on ILMN. Stifel Nicolaus boosted their target price on shares of Illumina from $235.00 to $265.00 in a research report on Wednesday, April 26th. StockNews.com assumed coverage on shares of Illumina in a research report on Thursday, May 18th. They set a hold rating on the stock. Finally, Robert W. Baird boosted their target price on shares of Illumina from $224.00 to $229.00 in a research report on Wednesday, April 26th. Two investment analysts have rated the stock with a sell rating, seven have issued a hold rating and seven have assigned a buy rating to the company. According to MarketBeat.com, the company has a consensus rating of Hold and a consensus target price of $235.26.
Read Our Latest Analysis on ILMN
Illumina Stock Down 2.5 %
Illumina (NASDAQ:ILMN – Get Free Report) last released its quarterly earnings results on Wednesday, August 9th. The life sciences company reported $0.32 earnings per share for the quarter, beating analysts’ consensus estimates of $0.02 by $0.30. Illumina had a negative net margin of 93.86% and a positive return on equity of 1.97%. The business had revenue of $1.18 billion for the quarter, compared to analysts’ expectations of $1.16 billion. During the same period last year, the business earned $0.57 EPS. The company’s revenue was up 1.2% compared to the same quarter last year. On average, equities analysts anticipate that Illumina will post 1.36 earnings per share for the current fiscal year.
Insider Activity at Illumina
In related news, SVP Susan H. Tousi sold 500 shares of the business’s stock in a transaction on Thursday, June 22nd. The shares were sold at an average price of $200.00, for a total value of $100,000.00. Following the completion of the transaction, the senior vice president now directly owns 46,522 shares in the company, valued at approximately $9,304,400. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Company insiders own 0.13% of the company’s stock.
Hedge Funds Weigh In On Illumina
Several large investors have recently made changes to their positions in ILMN. Luts & Greenleigh Group Inc. raised its position in Illumina by 0.6% during the first quarter. Luts & Greenleigh Group Inc. now owns 8,220 shares of the life sciences company’s stock worth $1,912,000 after acquiring an additional 50 shares during the period. Carnegie Capital Asset Management LLC raised its position in Illumina by 4.5% during the first quarter. Carnegie Capital Asset Management LLC now owns 1,171 shares of the life sciences company’s stock worth $272,000 after acquiring an additional 50 shares during the period. Eukles Asset Management raised its position in Illumina by 0.9% during the first quarter. Eukles Asset Management now owns 5,747 shares of the life sciences company’s stock worth $1,336,000 after acquiring an additional 51 shares during the period. Raymond James Trust N.A. raised its position in Illumina by 2.8% during the fourth quarter. Raymond James Trust N.A. now owns 1,883 shares of the life sciences company’s stock worth $381,000 after acquiring an additional 52 shares during the period. Finally, Kentucky Retirement Systems raised its position in Illumina by 0.4% during the fourth quarter. Kentucky Retirement Systems now owns 12,351 shares of the life sciences company’s stock worth $2,497,000 after acquiring an additional 54 shares during the period. 88.66% of the stock is currently owned by institutional investors and hedge funds.
Illumina Company Profile
Illumina, Inc develops, manufactures, and markets life science tools and integrated systems for large-scale analysis of genetic variation and function. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; and whole-genome sequencing kits, which sequence entire genomes of any size and complexity, and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.
Featured Articles
- Five stocks we like better than Illumina
- How to Invest in the FAANG Stocks
- Investing in Coffee: 3 Great Strategies to Consider
- Biggest Stock Losers – Today’s Biggest Percentage Decliners
- 5 Best Stocks to Buy in a Bear Market
- How to Find Cloud Software Company Stocks to Trade and Invest
- 3 Pharmaceutical Stocks to Buy and Hold for the Long Haul
Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.
